Introduction
Nanotechnology is a large, convergent, multidisciplinary enabling eld that is rapidly growing.
1,2 Size dependent properties due to spatial connement along with their high specic surface area and surface energies, give nanomaterials (NMs) unique, size dependent and tuneable electronic and optical behaviour. Such properties can be exploited in a range of applications including in nanomedicine, † which also utilise other nanoscale properties such as their ability to interact with the cellular machinery and potential for targeted cellular and sub-cellular compartmentalization. 3, 4 Applications of nanotechnology in healthcare can be as platforms for drug delivery, for enhancing outcomes of various treatment types such as photothermal therapy, thermal ablation and hyperthermia treatments, in vitro detection of biomarkers, imaging, and as combined drug and diagnostics devices -"theranostics" (for more details, see ref. [5] [6] [7] [8] .
Applications of nanotechnology can increase the efficacy of therapeutics by providing solutions to the traditional problems associated with pharmaceutical solubility, 9 limiting systemic toxicities, ‡ 10 bioavailability, 12 immunocompatibility 13 and cellular uptake.
14 Nanotechnology based therapeutics can be produced either through top down processes such as milling, high pressurised homogenisation, etching, lithography and other methods, or through bottom up processes, such as chemical synthesis both for inorganic NMs or complex polymeric designs to act as therapeutic agents or carriers of therapeutic agents. § These nanocarriers{ can be used to encapsulate and/or conjugate therapeutic agents like pDNA, siRNA and traditional chemotherapeutics (e.g., paclitaxel, doxorubicin, irinotecan) 9,15-17 which have had limited applications in clinical settings due to biological degradation, high systemic toxicities or other factors. Additionally, functionalization of the surface of these NMs using aptamers, antibodies, and cell receptor recognising proteins helps to achieve targeted drug delivery.
Nano-enabled in vitro diagnostic devices can help in the detection and early diagnosis of diseases like cancer (e.g., see a recent review, ref. 18 ) with increased sensitivity 19 and in a noninvasive manner. 20 In addition to in vitro diagnostics, nanotechnology is being used to develop new MRI contrast agents for in vivo diagnostics for contrast enhancement. For instance, a ten-fold increase in MRI contrast in comparison to clinical Gd(III) contrast agents e.g. Gd-DTPA and Gd-DOTA was observed by using nanodiamond conjugated to Gadolinium(III) [Gd(III)-ND]. 21 Due to these advantages, research and development investment of nanotechnology and nanomedicine has increased rapidly over the last 10 years, and it is likely that production and use of nanoenabled medical applications will rise in the coming years.
A recent, detailed study has estimated that there are currently 247 nanomedical products that have been approved and are in the market or are in early or late stages of clinical trials, with many more in development. 22 A market research rm, BCC research, has estimated that the nanomedical global market value increased from USD 53 billion in 2009 to USD 72.8 billion in 2011. Additionally, the rm has projected a compound annual growth rate in the global market for nanomedicines to be 12.5%, between the years 2011 and 2016, with largest growth in the therapeutic area of oncology and disorders of the central nervous system (CNS). 23, 24 The applications currently in clinical development belong to the categories of liposomal formulations, polymer-protein and polymer-drug conjugates, micelles, antibody-drug conjugates, dendrimers, metal and metal oxide NMs. Please see Table 1 exemplifying each of these categories.
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In this review, we discuss (i) the existing status of denitions of nanomedicine and a few relevant examples of nanomedicines under development, (ii) the current status of knowledge regarding environmental hazards and risks of conventional pharmaceuticals and nanomaterials with a view to understanding the environmental risks of nanomedicines, (iii) existing regulatory framework for pharmaceuticals for human use and medical devices and its coverage in the context of nanomedical applications and (iv) uncertainties and knowledge gaps. This paper focuses on nanomedical applications which are marketed or are in advanced stages of clinical development. The nanomedical applications that nd mention in the text belong to the category of therapeutics and diagnostics. Developments and clinical applications in regenerative nanomedicine are excluded in this review. There are a large number of proof-of-concept works related to nanocarriers based on fullerenes, carbon nanotubes, nanodiamonds, graphene, etc. which have immense potential for a myriad of applications in drug delivery. However, to the best of the knowledge of the authors, disease treatment strategies which have shown potential either in vitro or in proof-of-concept experiments using these materials are yet to move beyond preclinical stage, therefore, this paper doesn't focus on these materials. A lot of ecotoxicity research has been conducted on quantum dots (CdTe/CdSe as core), but these ecotoxicity studies are not being reviewed here because the use of quantum dots is not directly related to clinical applications. Of course, quantum dots are used in life sciences for cell imaging, tracking and elucidating biochemical mechanisms, hence they are important for medical research and innovation, but they are beyond the scope of this review. There is only one in vitro diagnostic device in the clinical trial phase which possibly uses SWCNT (single walled carbon nanotube), therefore, this paper also doesn't focus on the ecotoxicity research conducted on carbon nanotubes. The governance and regulatory framework explained in the text is EU centric and the paper refrains from touching upon other regulatory guidelines existing beyond the EU, unless exceptionally necessary to explain a particular section.
Nanotechnology in healthcare applications
The aim of nanomedicine is the comprehensive monitoring, repair and improvement of all human biological systems, working from the molecular level using engineered devices and nanostructures to achieve medical benet. The concept includes nanoscale active components or objects ranging in size from 1 nm to 100s of nm. 33 The European Commission's recommendation on the denition of nanomaterial creates a special case for pharmaceuticals and medical devices. The recommendation mentions that the proposed size cut-off value of 1 to 100 nm, with more than 50% of particles by number in this range, should not prejudice pharmaceutical and the medical devices sectors. 34 Thus, though mainstream nanotechnology explores particles between 1 and 100 nm in diameter, for nanomedicine, the size of the nanomaterials might in totality exceed 100 nm. The US FDA is yet to dene nanomaterial or nanomedicine. Therefore, a widely accepted and clear denition is essential for appropriate regulation of nanomedicine but is not in place as yet due to novelty and multidisciplinarity of the eld and broad range of applications that can be developed in the context of other convergent technologies. Nevertheless, rapid progress towards a denition is essential for regulatory purposes.
Nanomaterials are broadly classied into two categories based on the type of interactions exploited for designing nanomedicine. These two categories are 'hard' and 'so'. Hard nanomaterials are metal and metal oxide nanoparticles, fullerenes, etc. formed via ionic or covalent bonds, whereas 'so' nanocarriers use weak interactions. 35 The key types of hard nanomaterials currently being investigated for clinical applications and in the market are AgNPs, AuNPs and Fe x O y NPs. AgNPs has an antimicrobial effect and nds it uses in bandages for burn injuries, catheters and others. The potential for AuNPs in biomedical applications is due to its surface chemistry which makes it amenable to coating and functionalising with various targeting ligands, relative biocompatibility and photo-optical properties.
36 Fe x O y NPs are used because at nanoscale iron oxide exhibits super-paramagnetism and can be used as contrast agents as well as for hyperthermia treatments for cancer. 37, 38 Formulating metal and metal oxide NMs of different sizes and surface coating can help develop various biomedical applications.
The key types of 'so' nanocarriers in the market or in advanced stages of development are:
Liposomes are spherical vesicles composed of amphiphilic phospholipids and cholesterol, which self-assemble into bilayers to encapsulate an aqueous interior. They are one of the oldest and widely recognised nanocarriers and they can serve as a platform for delivery of both hydrophilic and hydrophobic therapeutic agents (see ref. 39 and references therein). Liposomes vary greatly in size from 25 nm to 5000 nm (ref. 40 ) and can be classied in terms of composition and mechanism of intracellular delivery into ve types: conventional liposomes, pH-sensitive liposomes, cationic liposomes, immunoliposomes, and long-circulating or PEGylated liposomes.
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Dendrimers are synthetic polymers (e.g. polyamidoamine, polypropylene imine) in which the atoms are arranged in many branches and sub-branches radiating out from a central core and sizes can be in the nm to mm range. Dendrimers can be categorized based on the number of the branches they possess which are called generations (G1, G2, G3, etc.). Dendrimers are being identied as ideal nanoscale drug delivery systems due their capacity to carry multiple modalities (therapeutic, imaging, and targeting). A plethora of different dendrimer compositions and chemical surface modications can be synthesized and dendrimers can themselves act as therapeutic agents (for further details, see ref. [42] [43] [44] .
Micelles are nanosized, spherical colloidal particles with a hydrophobic interior (core) and a hydrophilic exterior (shell). Drugs or contrast agents may be entrapped within the hydrophobic core or linked covalently to the surface of micelles (for examples, see ref. 45 ).
Nanocarrier design requirements: The key principles governing rational design considerations of nanocarriers are: 46, 47 physiologically stable nanocarriers capable of evading the reticuloendothelial system/mononuclear phagocytic system amenability to surface functionalisation with targeting moieties such as antibodies and cell penetrating peptides ability to cross the biological barriers of the body availability of a clearance mechanism that does not harm other organs ability to release the drug payload at the required site (delivery can also be designed so that it is modulated by pH or redox changes, enzymatic cleavage of bonds or activated by external stimulus such as electro-magnetic elds) biodegradability and biocompatibility, i.e., low or no immunotoxic, genotoxic, mutagenic, reproductive and developmental toxic effect for human beings.
These design features of nanocarriers will have the potential to increase therapeutic efficacy by protecting the therapeutic agents from being physically, chemically, biologically 'degraded' before they reach the disease target site and being released at this site. For instance, siRNA has been encapsulated in a 70 nm cyclodextrin based polymer, conjugated with a protein as a targeting ligand and polyethylene glycol (PEG) polymer to promote stability. 15 Design strategies can also help in escaping the biological barriers, have better control over drug release prole, increase absorption in tumours tissues, prevent therapeutic agents from interacting with normal cells and hence less systemic toxicities. [48] [49] [50] If these carriers are designed with the aim to treat CNS disorders, these features can also help the small drug molecules to cross the blood brain barrier and hence improve the therapeutic outcomes.
However, the design features necessary to make efficacious therapeutics might prove to have deleterious impacts on environmental biota and ecological health, when these medicines nd their way into the environment. Furthermore, not all design features listed above can be met for development of a particular therapeutic. For example, PEG coated therapeutics, so-called 'stealth' nanoparticles are in advanced stages of clinical trials, however it has been found that PEG is not easily biodegradable in the human body (mentioned in ref. 5 and 51) . At the same time, more targeted and in some cases reduced dosages might decrease the future environmental burden of conventional pharmaceuticals.
The context of existing pharmaceuticals and environmental risks
The primary focus of drug delivery research in nanomedicine has been to design delivery agents that would have the ability to cross the various biological barriers in the body and deliver therapeutic agents to the target site with the aim to increase therapeutic efficacy. The therapeutic agent might be conventional small molecule drugs which have found limited use in the clinic due to systemic toxic effects or poor solubility. This necessitates the review of the existing scientic literature on conventional pharmaceuticals in the environment. Concerns due to effects of pharmaceutical products (PPs)k in the environment have been expressed 91, 92 and this is now an active area of research. PPs from various therapeutic classes have been detected in the range of ng 99 and to a lower concentration and frequency in groundwater and drinking water sources. 100, 101 In many cases (see Table 2 ) concentrations of PPs has shown to exceed the current PEC sw ** threshold limit value of 0.01 mg L À1 suggested by the EMA. 102 PPs have also been found in aquatic biota. 32, 103, 104 The widely detected pharmaceutical products in the environment belong to the therapeutic class of antibiotics, non-steroidal anti-inammatory drugs, blood lipid lowering agents, sex hormones, central nervous system (CNS) disorder drugs and b-blockers (reviewed and summarized in ref. 105) . A few examples of the occurrence of pharmaceuticals and their metabolites in different environmental compartments are presented in Table 2 . Spatial, temporal and geographic variations (e.g., ref. 93, 106 and 107) have been shown to occur in the concentrations and type of pharmaceutical products. Fluctuations in the concentrations of pharmaceutical products have also been shown in effluents and receiving water bodies during special episodes, e.g., of disease outbreaks. 108, 109 In addition to monitoring campaigns, models such as SimpleTreat, LowFlow 2000-WQX, PhATE have been used to predict environmental concentrations in various compartments.
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Pharmaceuticals are metabolised and excreted out of the body either unchanged or in conjugated form (e.g. glucuronide, sulphates, glycinate conjugates) and hence the main sources for human pharmaceuticals and their metabolites in the environment have been identied as effluents of waste water treatment plants (WWTPs) from communities 112 hospitals 113 and pharmaceutical manufacturing facilities. 32 Approximately, 28% of the world's population in 2008 was not connected to sewage systems 114 and ca. 9% of the wastewater in EU countries is not treated or the waste water treatment systems do not have secondary treatment steps, 115 sewage systems are leaky 116 or contamination of storm water from waste water exists 117 thereby giving rise to the possibility of further environmental contamination. It has been established that the fate, removal and partitioning of these compounds are dependent on the design of the WWTP, 118 e.g., ibuprofen's removal efficiency was below 25% for a WWTP having primary treatment process compared with a removal efficiency of 90% in a WWTP having secondary treatment. 96 Furthermore, a few drugs have been shown to have negative removal percentages in the WWTPs, and it has been suggested that these negative removal percentages might be due to analytical instrumental errors, sampling variations, etc., but, it also gives credence to the hypothesis that the conjugated metabolites may undergo bio-transformation in the environment to form the parent drug (removal efficiencies in WWTPs has been reviewed in ref. 119) . PPs can also undergo abiotic transformations in the environmental matrices including photo-transformation and hydrolysis and can be deactivated to ecologically benign molecules or form harmful transformation products. For instance, the photo-transformation of diazepam and its metabolites was recently studied 120 and the investigators concluded that diazepam (a widely prescribed antidepressant) would be transformed under conditions present in the environment. However, the photoproducts that were identied had chemical structures similar to identied endocrine disruptors (photolytic and oxidative transformation of drugs has been reviewed in ref. 121) .
PPs like ibuprofen, acetaminophen, ciprooxacin, ketoprofen, etc. have high removal efficiencies in WWTPs which have secondary treatment steps. However, studies have also established that certain PPs (e.g. fenobrate and anthracyclines from the blood lipid regulator and anticancer therapeutic class respectively) sometimes get removed from the aqueous phase and get adsorbed to the sludge/solids. 122, 123 This may be due to hydrophobicity, binding interactions with particles in soils, etc. and thereby contributing to a new exposure pathway when this nutrient rich sludge is used for agricultural purposes.
Pharmaceuticals are designed to affect biological receptors and hence it should not come as a surprise that they have stimulatory or inhibitory or dual effects on non-target organisms upon exposure to different concentrations especially when the targets and biochemical pathways are similar. A well-known example of this is the ER-receptor agonist and antagonist behaviour associated with naturally occurring and synthetic hormones (e.g. ethinylestradiol-the active ingredient in the oral contraceptives) which can result in endocrine disruption. 124 Sometimes nontarget organisms, e.g. algae, cyanobacteria, which have nonrelated biochemical and metabolic pathways can also be effected upon exposure to pharmaceuticals. 125 Organisms might show limited toxicity in acute toxicity tests whereas higher toxicity in chronic tests for particular chemicals. 126 Mixture toxicity of PPs is of on-going concern as is their potential effects over many generations.
127 It has been observed that exposure to pharmaceutical products affects growth and behaviour of organisms, resulting in physical malformations, feminisation of males, changes in photosynthetic activity and metabolic processes. To date, very few ecotoxicity studies on pharmaceuticals have been conducted at environmentally relevant concentrations and hence there is inconclusive evidence to understand the true implications of their presence in the environment. See ref. 105 for a review of ecotoxicological studies of key pharmaceuticals. A key concern for nanomedicines is that their dual carrier and targeting functions may make existing PPs more bioavailable in the environment.
Early ecotoxicity studies reported toxicity effects at higher exposure concentrations and focused on growth inhibitory and reproductive effects. Recently, the shi in emphasis has been towards assessing impacts at low concentration and assessing the increased number of physiological biomarkers such as studying ROS production, transcription of genes, etc. For example, a decrease in nitrate reduction potential for groundwater bacterial communities was observed at 5 nM concentration of exposure to sulfamethoxazole 128 and changes in behaviour of marine amphipods by exposure to uoxetine (antidepressant, a selective serotonin reuptake inhibitor) at concentrations of 10 ng L À1 was reported. 129 A long term study in an experimental lake to assess the population level sustainability of the fathead minnow upon exposure to low levels (5-6 ng L À1 ) of synthetic estrogens 130 has shown that there can be collapse of a population due to feminization of the males. Various publications have suggested the need for assessing mixture toxicity [131] [132] [133] because of the additive, cooperative and antagonistic effects of different class and compounds of pharmaceuticals.
Many knowledge gaps have been identied which makes the task of conducting a plausible environment risk assessment for pharmaceuticals challenging. These gaps in knowledge create large uncertainties and hence inconclusive results. Furthermore, analytical challenges, e.g., non-extractable residues, interference by other contaminates in complex mixtures of sewage and hospital wastewater, and trace level of these compounds complicates the matter. We summarise here the few repeatedly mentioned knowledge gaps in the literature. Limited knowledge exists on:
occurrence, fate and activity of metabolites and their transformation products in the environment, mode of action of pharmaceuticals, metabolites and excretion rates long-term exposure to low levels of pharmaceuticals, ecosystem level impact, mixture toxicity exposure and effects data on soil organisms and marine species, effects data on ionic and polar compounds, and bioconcentration factors and bioaccumulation. Intensive research in the eld of environmental occurrence, fate and consequences of drugs and transformation products took off in the 2000s since the rst ndings of occurrence of [138] [139] [140] In January this year, the European Commission put forward the proposal to amend the Water Framework Directives to include three pharmaceuticals in the list of priority substances in Annex X of the Directive. 141 The positive outcome of the above-mentioned initiatives are that regulatory steps are being taken, however, it also exemplies the time lag between knowing, proving environmental impacts and development or amendment of regulatory guidelines.
This table gives a very small number of the different types of pharmaceuticals monitored in the environment. It is meant to provide to the reader an overview of measured concentrations from recently published studies (2009) (2010) (2011) (2012) , the different environmental compartments where PPs have been found, and in different regions of the world. For detailed reviews on occurrence, fate and ecotoxicity of pharmaceuticals and their metabolites the reader is suggested reviews elsewhere, e.g., ref.
105, 121 and 161-163.

Possible sources, fate and effects of nanomaterials (NMs) † † in the environment
The continued thrust on nanotechnology as an innovation and economic driver ‡ ‡ 164 will result in development of a larger number of new and complex materials and will inevitably result in release of these materials in the workplace 165 and subsequently in the environment. 166 The possible entry routes of NMs in the environment includes intentional (e.g., for remediation purposes) or accidental releases, emissions from manufacturing facilities, abrasion and weathering of NMs containing products. The specic entry route into a particular environmental compartment will depend on the life cycle of the product and disposal method used, for example, washing of nanofunctionalised textiles will result in release of the NMs in the sewerage system and nally transportation to natural waters. 167 To the best of the knowledge of the authors, no actual eld level environmental monitoring of NMs have been reported in the literature, though model environmental concentration estimates have been calculated and reported for selected NMs.
168
As is the case of pharmaceuticals, NMs also give rise to transformation products in various environmental conditions. The type of transformation products that will form will depend on the nanoscale properties of the NMs and on the conditions of the environmental matrices, e.g., magnetic iron nanoparticles aggregate at near neutral pH due to their near neutral zeta potential but at higher pH they are more dispersed. 169 The key transformation mechanisms can be aggregation (homoand hetero-aggregation), dissolution, oxidation/reduction and adsorption.
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Under simulated situations it has been found that natural organic matter (NOM) like humic substances 171 179 It has also been demonstrated that silver NPs in organic matter rich soil become more bioavailable aer aging. 180 In addition to NOM, physico-chemical properties of the aqueous environmental compartment like pH, ionic strength, salinity, mineral content/hardness, etc. have also been shown to inuence fate, behaviour and toxicity. For instance, it was shown that E. coli survived at pH 10 even at concentrations of iron oxide NPs (b eq of 109 mg L À1 of FeO x ), however, S. cerevisiae (an eukaryote) had survival rates of less than 10%.
181
Hardness of water, at near neutral pH, can result in formation of aggregates and biouptake by lter feeders 182 or settling down and available to pelagic organisms or earthworms. High total organic carbon (TOC) and low ionic strength, conditions in freshwaters, can stabilise NMs and make it persistent and be available for lter feeders, sh and algae and low TOC and high ionic strength such as in sea water can aid in their rapid aggregation and settling.
183 Please see ref. [184] [185] [186] [187] for further studies on possible fate, behaviour and effects of engineered nanomaterials in the environment.
The key factors inuencing toxicity are composition, size, surface properties (both for the NM and the transformed products), sensitivity of the species and presence of other contaminants. For example, cationic branched polymer [polyethyleneimine (PEI)] coated AgNPs (10 nm) was shown to have increased toxicity to a Gram +ve bacterium, bacillus sp. when compared to citrate and PVP coated AgNPs. 188 Similarly, positively charged AuNPs of 2 nm size was reported to lyse Bacillus subtilis, but observed to have no effect on E. coli, a Gram Àve † † In this review, nanomaterials (NMs) refer to all engineered or manufactured nanomaterials and do not cover incidental or natural nanomaterials. There is some understanding of manufactured NM fate and behaviour and nanomedicines, where there is little direct information, are a sub-set of NMs; therefore we focus on engineered NMs in this section to highlight potential nanomedicine behavior. 189 Bioaccumulation and trophic transfer of NMs can also happen. 190, 191 Many investigators have shown biolms to be an effective sink for NMs 190, 192, 193 and aquatic organisms like lter feeders to uptake and biotransform suspended and dispersed NMs present in the aquatic matrix. 194, 195 Furthermore, exposure of organisms to NMs would be dependent on the presence of other environmental contaminants, mode of action of the chemical and the differences in physiology of species. Phenanthrene adsorbed on n-C60 was shown to be more bioavailable to algae and daphnids, but was found to be more toxic to algae 196 and the investigators suggested the difference in physiology to be the reason for this observation. Whereas, n-C60 fullerenes was shown to sequester the synthetic hormone, 17-a ethinylestradiol (EE2) hence reducing its bioavailability.
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Similarly, it was demonstrated that mixed iron oxide NMs in organic matter rich environment (humic acid >20 mg L À1 ), low salinity (tap water and deionised water), and in a pH range of 5-7 could adsorb the antibiotic chlorotetracycline. 198 Interactions between hydrophobic NMs and pharmaceutical products can sequester PPs from the environment hence reduce or increase their bioavailability in a given time frame.
Possible sources, fate and effects in the environment of nanomedicines
There is insufficient knowledge regarding possible amounts and entry routes of nanomedicine products in the environment, however it should not deter one from making estimates of likely routes of entry, based on knowledge of environmental release and transport of pharmaceuticals. Fig. 1 is a conceptual model of likely release and exposure pathways of nanomedicine and a key research issue is to quantify the concentrations and uxes within this conceptual model. There are different entry routes for various medical NMs in the environment. In case of therapeutic applications, the obvious route is the renal and the hepatobiliary § § routes of excretion to domestic sewage and then subsequently to waste water treatment plants and to receiving water bodies and land (with the caveat mentioned earlier that a large percentage of waste water even in the EU goes untreated). Other possible routes are likely to be NM release into the air from inhalers, disposal of unused medicine at hospitals, R&D labs, and clinical research facilities by casual and ill trained staff, NM release during manufacturing, transport and accidental spills, and from the incinerators. Due to high specic surface areas NMs might get adsorbed on to waste solids of the combustion chamber in an incinerator or be present in the off-gas. 199 However, complete removal of NPs below 100 nm from the off gas of the incinerator might not happen, even aer state-of-the art effluent gas treatment processes.
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In case of medical devices, improper disposal of the devices at end of their life, especially disposable of in vitro diagnostic products is likely to release NMs into the environment. Although we know quantitatively very little at the moment, a priori it might be expected that certain pathways are likely to be Fig. 1 A conceptual schematic showing likely sources and transport of nanomedicine into the environment. Nanomedicines and transformed products may be released into the water through the excretory routes, washing off from skin, from manufacturing facilities, spillages and disposal of product. They can be released in the atmosphere from nasal inhalers. Incineration of composite medical products and abrasion and weathering in landfills may lead to release into the atmosphere.
of major importance, including: (1) waste water and storm water to waste water and sludge and then to freshwater and soil; (2) treated ue gas from incineration to atmosphere and then to water and soil and (3) landll to groundwater and soil and then to surface water.
Biotransformation and excretion
Ingested and injected PPs are amenable to biotransformation in the body due to the action of various enzymes and are excreted primarily with urine and/or faeces. 201 Studies have been performed to nd out the clearance mechanisms of NMs with prospective use in medicine. Biodistribution studies with gold nanoparticles have been conducted by different investigators and it has been found that the clearance pathway is dependent on size, surface coating and charge of the particle. Lipka et al. 202 showed that 10 kDa PEG coated 5 nm AuNPs followed the hepato-biliary clearance route, whereas another study 203 showed uncoated 20 nm AuNPs to be primarily recovered in the urine. A recent study showed that hepato-biliary clearance was inversely related to negatively charged AuNPs of different sizes (1.4, 2.8, 5, 18, 80, 200 nm). The investigators concluded that the small sized negatively charged AuNPs were excreted out via the hepato-biliary excretion pathway because of "dynamic protein binding and exchange which are major mechanisms determining the AuNP accumulation in the various organs and tissues.". 204 By extension, there might be differences in biodistribution prole of encapsulated and free drug. A study showed that urinary excretion of the unaltered drug when encapsulated in poly-epsilon-caprolactone (a widely researched polymer for medical applications) nanocarriers increased by $15% in comparison to the administration of non-encapsulated drug, 205 hence would result in more discharge to the environment unless dosages are altered. Biological fate of a model PEG-protein was studied and it was found that 46.5% of PEG of the administered dose was excreted out of the urine over a period of few days. The same study also reported that intact PEGylated model protein was excreted out in the rst few days post administration of the model protein.
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In many cases, nanoformulations help to reduce systemic toxicities especially for anticancer drugs. For example, nabpaclitaxel, a nanomedicine in the market, is a formulation of paclitaxel (empirical formula: C 47 H 51 NO 14 , a plant alkaloid) bound to albumin nanoparticles with mean particle size 130 nm has been shown to have better therapeutic efficacy than conventional paclitaxel (TaxolÒ) for breast cancer. The dosage of this new formulation is 260 mg m À2 of body surface area every 3 weeks (Taxol's prescribed dosage ranges from 135 mg m À2 to 175 mg m À2 of body surface area every 3 weeks), 207, 208 showing the possibility of higher doses that can be achieved through nanoformulation. Traditional chemotherapeutics are highly hydrophobic drugs, and hence are generally assumed to be adsorbed on to the sludge of STP 123 and then mainly incinerated or spread on agricultural soils (Switzerland and UK, respectively). The possibility of administering increased dosages and changed excretion proles due to the new nanoformulations will likely increase the environmental concentration of these highly cytotoxic pharmaceutical products. The above examples indicate the likely problem areas; however, the authors acknowledge the fact that more targeted medicines, customised for small populations (personalised medicines) and possibility of reduction in premedication amounts might result in a more favourable benet-risk balance when all aspects are taken into consideration.
Fate and behaviour
Polymer coating on NMs will affect the fate and behaviour of NMs in waste water treatment plants. Tween 20 coated silica oxide nanoparticles ($56 nm) were shown to remain in the sludge, whereas uncoated silica oxide NP did not occulate and remained in the effluent. 209 Biolms can act as potential 'sinks' for NMs either in the secondary treatment stage of a sewage treatment plants or in fresh water ecosystems. Sometimes, the polyethylene glycol (PEG) coating on NM can integrate itself with the protein component of the biolm and change the roughness co-efficient of the biolm but shielding the toxic effects of the core particle. 192 The size can also have an inuence of changing the morphological properties of a biolm. Stojak et al. reported an increase in roughness coefficient and significant decrease in plankton biomass in a L. pneumophila mature biolm aer 2 days of exposure to citrate capped of Au nanoparticles of sizes 4 and 18 nm. 193 However, no change was observed in the biolm exposed to 50 nm gold NPs. Furthermore, it was observed that the 4 nm and 18 nm AuNPs got adsorbed onto the exopolysaccharides of bacterial cell wall and also got entrapped in the bacterial cell.
193 Polymers may be utilised as carbon/energy sources. It was recently demonstrated that PEG coated NM could be degraded by bacteria from an urban stream. However, the degradation rate and aggregation depended on the available chain end groups of the two different types of polymer coated NMs studied.
210 Polymer (poly ethylene glycol-b-3-caprolactone) coated nanoparticles were found to irreversibly adsorb onto cellulosic surface and the adsorption mechanism was found to be size dependant. The investigators hypothesised that adsorption could be due to interdigitation and entanglement of the nanoparticles with the D-glucose chains of cellulose.
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Biouptake and effects
Monodispersed, stable and targeted nanomaterials are important for medical applications, e.g., monodispersed iron oxide nanoparticles 7, 212 to fully exploit their novel properties, increase shelf life and to inuence physiological responses with increased effectiveness. These same design requirements may dictate the fate and risk of the nanomaterial in the environment by not only arresting growth and reproduction, but also interfering with metabolic processes and hence in turn impacting key ecosystem services. However, to a certain extent organisms might be able to tolerate the exposure of nanomedicines although this is poorly quantied.
Nanoparticles are coated with organic polymer coatings to escape the mononuclear phagocytic system in the body ('stealth' properties) or to especially target cells. There are 
The 'nano' component in nanomedicine Short description of select ecological studies of toxicity effects, uptake and bioaccumulation for NMs and nanocarriers with likely use in nanomedicine References
Polyethyleneimine (PEI) polymer
For tadpole larva, Xenopus laevis, both PEI and PEI:DNA (polyplex) showed teratogenic effects at concentrations 0.1 mg L À1 . PEI also showed higher toxicity for the algae Pseudokirchneriella subcapitata;
The polyplex was found to be less toxic to the algae than the free polymer 213 Dendrimers Commercially available amine terminated G4 dendrimer showed sublethal toxicity in zebrash embryos at 0.2 mM concentrations, whereas COOH terminated G3.5 dendrimers did not exhibit toxicity even at concentrations of 200 mM. Dose and time dependant mortality was observed for amine terminated G4 dendrimer, 100% mortality at dose 20 mM in 24 h post fertilisation
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Green algae Chlamydomonas reinhardtii exposed to commercially available amine terminated G2 (2.6 nm), G4 (4.4 nm), G5 (5.7 nm) poly(amidoamine) PAMAM dendrimers showed decreased cell viability at 2.5 mg L À1 (median IC 50 as per dendrimers generation:
evolution from photosynthesis signicantly increased at concentrations 1 mg L À1 and 2.5 mg L À1 for G2
and G4 dendrimer (increase in PSII reaction centres and e À transport). A dose-effect study of amine terminated G4 and G1 PAMAM dendrimers with ethylenediamine core was conducted for P. subcapitata. The amine-terminated G4 dendrimer was found to be comparatively more toxic than the amine terminated G1 dendrimer. The negatively charged hydroxyl terminated G4 dendrimer had least toxicity No magnetism was observed in the shoots of both the plants, indicating, that the iron NPs were not translocated. The oxidative stress enzyme superoxide dismutase activity was found to be higher in the roots of both the plants for iron bulk and nanoparticles at 30 mg L À1 concentration
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In the presence of sublethal concentrations of As(V) (to rule out the probability that environmental arsenic is causing the toxicity), commercial nano-Fe 2 O 3 (20-40 nm) was shown to have increased toxic effect on C. Dubia. It was established nano-Fe 2 O 3 and As(V) caused the toxic effect in a synergistic mode (nano-Fe 2 O 3 alone didn't exhibit mortality under the concentrations used in the study). It was found that 48 hour mortality was dose dependant but 24 h mortality was not. At 20 mg L À1 of nano-Fe 2 O 3 , the 48 hour mortality increased from 30% to 70% and then the mortality rate remained nearly constant for higher exposure doses. Depuridation (upto 75%) occurred aer an hour for solutions having algal feed. It was observed that maximum bioaccumulation occurred at neutral pH. limited numbers of ecotoxicity studies which have been conducted with polymers used in medical applications, of the few that we are aware of, most of the studies have been done on dendrimers.
Dendrimer toxicity has been shown to increase with increase in the generation of cationic dendrimers for various model organisms (D. magna, V. scheri, P. subcapitata, T. platyurus). Table 3 gives a summary of selected ecotoxicity studies which can be linked with NMs used in medical applications. The environmental sources, fate and effects of AgNPs have been widely reported in the scientic literature and therefore this table does not cover ecotoxicity studies of AgNPs. Readers are referred elsewhere for a review on fate and effects of AgNPs in the environment.
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Regulatory framework for medicines and medical devices in the EU
Regulations for pharmaceuticals for human use
Extensive studies for assessing toxicity are conducted aer identication of a promising new entity that has a therapeutic potential. A battery of tests and assays are performed to ) and time (48, 72, 96 h ).
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Contents of chlorophyll-a and b decreased by 86.4% and 94.8% as compared to the control group, but the amount of carotenoids didn't decrease. Exposure duration: 96 h of exposure at 50 mg mL understand whether there are risks for human carcinogenicity, genotoxicity, reproductive and development toxicity, immunotoxicity, etc.). Pharmacodynamics and pharmacokinetics studies are conducted in small animal models to assess the distribution of the drug, the mode of action and physiological effects, metabolism and excretion. Data from these studies is required to be submitted to the relevant medical regulatory agency before enrolling human subjects to establish the safety and efficacy (Phase I to Phase III clinical trial) of the new drug. The preclinical and the clinical trial data form the basis of the marketing authorisation application (MAA) in the EU and member states. Applications for therapeutics for cancer, neurodegenerative diseases, HIV/AIDS and immune dysfunctions, and viral diseases are submitted to the centralised medical regulatory agency in the EU, the European Medicines Agency. A few other therapeutics which go through the centralised procedure include officially designated 'orphan'{{ medicines, biotechnology based therapeutics, tissue engineering products. Marketing surveillance ('pharmacovigilance') of the medicine post authorisation are other regulatory steps which should help to monitor the therapeutic agent's safety. Fig. 2 is a simplied depiction of the medicine innovation pathway, key checkpoints with regard to regulatory agency involvement and the underlying guidelines for ethics and safety during innovation. The decision for approving a medicine is based on the careful evaluation of the benet-risk assessment of a particular therapeutic for the target group of patients.
Medical devices legislation
The regulatory context with regard to medical devices in the EU is substantially different to that of medicines for human use. Medical device and medicine regulatory pathway have distinct and clearly demarcated regulatory process. The medical device directives are implemented at EU member state level with no overarching body at the EU level. There are three different regulations to capture all the different types of devices used in the medical industry -the Medical Devices Directive, Active Implantable Medical Device Directive, and In Vitro Diagnostic Medical Device Directive. Combination products i.e. integration of a medical device and medicine, spurred by nanotechnology, has blurred the distinction between the two distinct regulatory pathways and need for revisions in the current legal framework has been voiced in the public consultation process, a part of the undergoing process of revision (2008-onwards) of the medical devices directives. Also, few member state regulators (e.g. UK, Sweden) have taken required steps towards addressing the issue.
Medical devices are classied according to their perceived level of risk -Class I representing the lowest level of expected/ Fig. 2 General stages of nanomedicine development and the key points of interaction between regulatory agencies and nanomedicine developers. Good Laboratory Practices, Good Manufacturing Practices, Good Clinical Practices are the quality and ethical guidelines followed by pharmaceutical companies and researchers and monitored by regulators. Rapid advancement in technology and science and need for innovation to be an economic driver, regulatory agencies are present in earlier stages of product development.
{{ To qualify for orphan designation, a medicine must meet one of these criteria (as dened by the EMA, ref. 234): (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than 5 in 10 000 people in the EU at the time of submission of the designation application; (2) it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and without incentives it is unlikely that the revenue aer marketing of the medicinal product would cover the investment in its development.
perceived risk and Class III representing the highest level of risk. The degree of risk assigned then determines the level and type of evidence required for award of CE (Conformité Européenne) mark. Clinical data is required for awarding a CE mark for Class III medical devices but are not mandatory; literature analysis showing clinical investigations and experience related to similar devices and appropriate justication can be used for submission of application for approval. 235 Tests to identify human toxicological risks from materials used in medical device components, (e.g. polymers) need to be performed. However, no environmental risk assessment of medical devices is required. Unfortunately, the medical devices directives do not cover the entire life cycle of the product and their disposal in the EU was according to the WEEE Directive (Waste Electronic and Electrical Equipment Directive 2002/96/EC) which did not mandate recycling and recovery percentages for medical devices giving rise to the concern that similar environmental and occupational health problems as electronic waste 236 may occur for the use of cost-effective mass produced nano-enabled in vitro diagnostic tools. However, the recently revised WEEE Directive has mandated recovery and recycling targets for certain medical devices.
237
Current regulatory context (human medicines) related to environmental safeguard
The European Medicines Agency's Guideline on Environmental Risk Assessment (ERA) of pharmaceuticals 102 follows a tiered assessment approach: Phase I and Phase II (Tier A and Tier B). Fig. 3 gives a concise schematic explanation of the approach. An ERA needs to be provided with every new marketing authorisation application (MAA) for a pharmaceutical; however, granting of market authorisation is independent of environment impact. There are two initial pre-screening steps -(a) if the predicted environment concentration of the pharmaceutical exceeds the threshold value of 0.01 mg L À1 (0.01 ppb), then it triggers the need for conducting few acute ecotoxicity tests on regulatory species to calculate the Predicted No Effect Concentration (PNEC) (b) if the octanol-water partition co-efficient (log K ow ) is greater than 4.5, persistence, bioaccumulation and toxicity (PBT) assessment tests need to be conducted by following ECHA's guidance on chemical safety assessment. Firstly, the questions arise, how is the PEC calculated for nanomedicines? Apart from concerns which are similar to all NMs, should it to be based on the drug, the nanocarrier or on the nanocarrierdrug conjugate? How would the PEC be derived for more complex nanomedicines? As with all NMs, nanomedicines may present unique concerns and the applicability of such ERAs have not been fully demonstrated. Secondly, it is well established that log K ow has deciencies as a surrogate for determining mobility and partitioning of PPs or for application to NMs. 238 For example, the antidepressant carbamazepine was found in sh tissues from effluent dominated streams though the drug has a log K ow of 2.67. Similarly, ciprooxacin, an antibiotic, sorbs well onto active sludge or 
sediments,
153,239 despite a log K ow of À1.74 (cited in ref. 240 ) and it was found to be persistent. 241 It has been widely debated that log K ow for acidic and basic drugs is misleading, because the coefficient is dependent on solution pH, ionic strength, NOM and other factors. In the case of NMs, the inadequacy of the test protocol to determine log K ow has been discussed. 238 A study performed on different generations of dendrimers showed that for dendrimers with terminal NH 2 group, the log K ow of the polymer was negative for G1-G5 PAMAM dendrimers and G6-NH 2 and G8-NH 2 dendrimers partitioned at the octanol-water interface. 242 The negative log K ow indicates that under the current ERA guidelines, there will not be any need to conduct a TIER 1 risk assessment. Similarly, PEG has negative log K ow and it doesn't change much with the chain length, furthermore, it is not easily biodegradable.
Although the action limit 0.01 mg L À1 is very low, it is based on acute rather than chronic toxicity tests and it has been widely discussed both for pharmaceuticals and nanomaterials, that chronic and sub-lethal toxicity end points are important to assess the environmental risks of the product and that the link between chronic and acute toxicity is not well established for NMs. Furthermore, the test protocols suggested in the ERA Guidelines for human pharmaceuticals for conducting the physical-chemical fate and effects studies is based on OECD test guidelines for chemicals. The recommended study types include adsorption-desorption using a batch equilibrium method, a ready biodegradability test, aerobic and anaerobic transformation in aquatic test, algae growth inhibition, daphnia reproduction test, etc. The drawbacks and the need for adaptability of the current OECD tests and protocols, originally meant for chemicals, with respect to NMs have been discussed and reviewed. 243, 244 Key issues are the inuence of the test medium conditions on the NMs, 245-247 the need to include benthic and lter feeding organisms as test species, the necessity of investigating chronic effects and nding novel toxicity end points, the need for extensive in situ physicochemical characterisation, the limited applicability of the persistence and bioaccumulation tests. The applicability of testing to nanomedicines will include the same issues and perhaps other specic ones including role of the nanocarrier in increased uptake.
Knowledge gaps and uncertainties and conclusion
Despite much progress in recent years, knowledge and data gap exists for pharmaceuticals, including their metabolic products and excretion rate, and their environmental fate and behaviour, removal efficiencies in sewage treatment plants, chronic toxicity data and bioaccumulation. 136 In nanotoxicology and nanoecotoxicology, the key gaps include environmental concentrations, environmental fate and behaviour, dynamic changes in physical and chemical properties both in vitro and in vivo, applicability of exposure assays, dose metrics for exposure assessment, biouptake and toxicity mechanisms and chronic/ acute toxicity relationships. [185] [186] [187] 243 In nanomedicine, all these gaps in knowledge and data apply, along with others such potential discharges to the environment and medium term growth in applications. Given the signicant potential benets of nanomedicine such as potential for dose reduction, it is imperative to further understand any potential environmental risks to allow the long term safety, sustainability and development of the industry. However, further understanding of the impacts of nanomedicine in the environment can be provided by use of data from the pharmaceuticals, environmental and nanoscience elds. In addition, sophisticated models and techniques are available which can be applied and adapted to understanding the environmental implications of nanomedicine. Although caution needs to be exercised as there will be discipline-dependent differences, such methods, data and models provide a solid platform for future more specic studies which are urgently needed.
